{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:41:52Z","timestamp":1773070912330,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2684,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mds348","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T04:24:49Z","timestamp":1347855889000},"page":"x237-x242","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S10","title":["Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers"],"prefix":"10.1016","volume":"23","author":[{"given":"B.","family":"Sousa","sequence":"first","affiliation":[]},{"given":"F.","family":"Cardoso","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds348_bb0010","first-page":"3","article-title":"Indications for neoadjuvant chemotherapy for breast cancer","volume":"25","author":"Bear","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1097-0142(19830301)51:5<763::AID-CNCR2820510502>3.0.CO;2-C","article-title":"Multimodal treatment of locoregionally advanced breast cancer","volume":"51","author":"Hortobagyi","year":"1983","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds348_bb0020","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D","article-title":"Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy","volume":"62","author":"Hortobagyi","year":"1988","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds348_bb0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/1097-0142(19900915)66:14+<1387::AID-CNCR2820661414>3.0.CO;2-I","article-title":"Comprehensive management of locally advanced breast cancer","volume":"66","author":"Hortobagyi","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds348_bb0030","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical adjuvant Breast and Bowel Project B-18","volume":"30","author":"Wolmark","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1093\/annonc\/mds348_bb0040","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical adjuvant Breast and Bowel Project Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0045","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902","volume":"19","author":"Van der Hage","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0050","doi-asserted-by":"crossref","unstructured":"Mieog S, van der Hage J, van de Velde CJH. Preoperative Chemotherapy for Women with Operable Breast Cancer (Review) 1. John Wiley & Sons, Ltd. January 24 [epub ahead of print], DOI: 10.1002\/14651858.CD005002.","DOI":"10.1002\/14651858.CD005002"},{"key":"10.1093\/annonc\/mds348_bb0055","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0060","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0065","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdm008","article-title":"Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers","volume":"18","author":"Mazouni","year":"2007","journal-title":"ann Oncol"},{"key":"10.1093\/annonc\/mds348_bb0070","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.20.6.1456","article-title":"Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0075","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mdi001","article-title":"In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPaRTRIO pilot study","volume":"16","author":"von Minckwitz","year":"2005","journal-title":"ann Oncol"},{"key":"10.1093\/annonc\/mds348_bb0085","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","article-title":"Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study","volume":"28","author":"von Minckwitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/jco.2006.24.18_suppl.576","article-title":"Comparison of neoadjuvant 6 vs 8 cycles of docetaxel\/doxorubicin\/cyclophosphamide (TaC) in patients early responding to TaCx2-the GEPaRTRIO Study","volume":"24","author":"Von Minckwitz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0095","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.2004.05.207","article-title":"The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1093\/annonc\/mds348_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/0008-5472.SABCS-79","article-title":"Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +\/- trastuzumab containing chemotherapy","volume":"69 (","author":"von Minckwitz","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds348_bb0110","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","article-title":"Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer","volume":"91","author":"Ring","year":"2004","journal-title":"Br J Cancer"},{"issue":"suppl 1, abstr S35","key":"10.1093\/annonc\/mds348_bb0115","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0960-9776(03)80035-8","article-title":"Preoperative systemic treatment: Prediction of responsiveness","volume":"12","author":"Colleoni","year":"2003","journal-title":"Breast"},{"key":"10.1093\/annonc\/mds348_bb0120","series-title":"Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIaL (CaLGB 150007\/150012, aCRIN 6657)","author":"Esserman","year":"2009"},{"key":"10.1093\/annonc\/mds348_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds348_bb0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.2007.15.4716","article-title":"HER-2 and topoisomerase II as predictors of response to chemotherapy","volume":"26","author":"Pritchard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0135","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(11)70231-5","article-title":"HER2 and TOP2a as predictive markers for anthracycline containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","volume":"12","author":"Di Leo","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds348_bb0140","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds348_bb0145","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","article-title":"HER2 and response to paclitaxel in node-positive breast cancer","volume":"357","author":"Hayes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds348_bb0150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdg108","article-title":"Locally advanced\/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?","volume":"14","author":"Bonnefoi","year":"2003","journal-title":"ann Oncol"},{"key":"10.1093\/annonc\/mds348_bb0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mdg104","article-title":"Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer","volume":"14","author":"anelli","year":"2003","journal-title":"ann Oncol"},{"key":"10.1093\/annonc\/mds348_bb0160","first-page":"2751","article-title":"p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients","volume":"6","author":"Bottini","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds348_bb0165","first-page":"955","article-title":"automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response","volume":"9","author":"Davis","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1093\/annonc\/mds348_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1470-2045(11)70094-8","article-title":"TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994\/BIG 1\u201300): a randomised phase 3 trial","volume":"12","author":"Bonnefoi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds348_bb0175","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0180","first-page":"3646","article-title":"Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis","volume":"59","author":"Johnston","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds348_bb0185","first-page":"50","article-title":"TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients","volume":"6","author":"Kandioler-Eckersberger","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds348_bb0190","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.1073\/pnas.1732912100","article-title":"Breast cancer classification and prognosis based on gene expression profiles from a population-based study","volume":"100","author":"Sotiriou","year":"2003","journal-title":"Proc Natl acad Sci USa"},{"key":"10.1093\/annonc\/mds348_bb0195","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl acad Sci USa"},{"key":"10.1093\/annonc\/mds348_bb0200","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van't Veer","year":"2002","journal-title":"Nature"},{"key":"10.1093\/annonc\/mds348_bb0205","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","article-title":"Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer","volume":"362","author":"Chang","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds348_bb0210","first-page":"237","article-title":"Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel\/FaC chemotherapy in breast cancer","volume":"21","author":"Pusztai","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0215","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1200\/JCO.2005.01.2898","article-title":"Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer","volume":"23","author":"Rouzier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0220","doi-asserted-by":"crossref","unstructured":"Von Minckwitz G, Kaufman M, Kuemmel S et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. ASCO MEETING ABSTRACTS June 9, 2011: 1028.","DOI":"10.1200\/jco.2011.29.15_suppl.1028"},{"key":"10.1093\/annonc\/mds348_bb0225","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.2010.31.2231","article-title":"Multifactorial approach to predicting resistance to anthracyclines","volume":"29","author":"Desmedt","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0230","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2011.39.5624","article-title":"Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis","volume":"30","author":"Ignatiadis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0235","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006","volume":"18","author":"Kaufmann","year":"2007","journal-title":"ann Oncol"},{"key":"10.1093\/annonc\/mds348_bb0240","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","volume":"13","author":"Buzdar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds348_bb0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds348_bb0255","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0260","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoaLTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds348_bb0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds348_bb0270","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study","volume":"30","author":"Guarneri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24 Suppl.","key":"10.1093\/annonc\/mds348_bb0275","article-title":"Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (\u2018NeoSphere\u2019)","volume":"70","author":"Gianni","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds348_bb0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds348_bb0285","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.breast.2011.09.006","article-title":"Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design","volume":"21","author":"Eiermann","year":"2012","journal-title":"Breast"},{"key":"10.1093\/annonc\/mds348_bb0295","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1002\/cncr.25309","article-title":"Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment","volume":"116","author":"Chang","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds348_bb0300","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00280-007-0652-z","article-title":"Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fuorouracil followed by weekly paclitaxel","volume":"62","author":"Torrisi","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mds348_bb0305","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCa-1 positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0310","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0315","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2009.25.9549","article-title":"Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer","volume":"28","author":"Colleoni","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds348_bb0320","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds348_bb0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419417845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419417845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/suppl_10\/x237\/6685310\/mds348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T16:56:34Z","timestamp":1687712194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419417845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":64,"alternative-id":["S0923753419417845"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds348","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}